4-(4-cyclopropylpyrimidin-5-yl)-1-(4-fluorophenyl)pyrazolo[3,4-b]pyridine

ID: ALA5289188

Max Phase: Preclinical

Molecular Formula: C19H14FN5

Molecular Weight: 331.35

Names and Identifiers

Canonical SMILES:  Fc1ccc(-n2ncc3c(-c4cncnc4C4CC4)ccnc32)cc1

Standard InChI:  InChI=1S/C19H14FN5/c20-13-3-5-14(6-4-13)25-19-17(10-24-25)15(7-8-22-19)16-9-21-11-23-18(16)12-1-2-12/h3-12H,1-2H2

Standard InChI Key:  KHBCFZVFFYZFRB-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 25 29  0  0  0  0  0  0  0  0999 V2000
   -1.5420    0.8768    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5436    0.0518    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2588   -0.3593    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8298   -0.3620    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1146    0.0491    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1131    0.8741    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8268    1.2879    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5029   -0.5232    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.1709   -1.2570    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6528   -1.1631    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3000   -0.3096    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5139    0.4874    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3088    0.6996    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8925    0.1159    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6815   -0.6776    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8860   -0.8956    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6896    0.3295    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2602   -1.1845    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9757   -1.5958    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6896   -1.1819    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6881   -0.3567    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9727    0.0545    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9727    0.8798    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5593    1.5958    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3845    1.5949    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  2  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  1  1  0
  5  8  1  0
  8  9  1  0
 10  9  2  0
  4 10  1  0
  8 11  1  0
 12 11  2  0
 13 12  1  0
 14 13  2  0
 15 14  1  0
 16 15  2  0
 11 16  1  0
 14 17  1  0
 18  3  2  0
 19 18  1  0
 20 19  2  0
 21 20  1  0
 22 21  2  0
  3 22  1  0
 22 23  1  0
 24 23  1  0
 24 25  1  0
 23 25  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA5289188

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 331.35

Molecular Weight (Monoisotopic): 331.1233

AlogP: 3.89

#Rotatable Bonds: 3

Polar Surface Area: 56.49

Molecular Species: NEUTRAL

HBA: 5

HBD: ┄

#RO5 Violations: ┄

HBA (Lipinski): 5

HBD (Lipinski): ┄

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 1.87

CX LogP: 3.01

CX LogD: 3.01

Aromatic Rings: 4

Heavy Atoms: 25

QED Weighted: 0.57

Np Likeness Score: -1.58

References

1. Padmakar Darne C, Velaparthi U, Saulnier M, Frennesson D, Liu P, Huang A, Tokarski J, Fura A, Spires T, Newitt J, Spires VM, Obermeier MT, Elzinga PA, Gottardis MM, Jayaraman L, Vite GD, Balog A..  (2022)  The discovery of BMS-737 as a potent, CYP17 lyase-selective inhibitor for the treatment of castration-resistant prostate cancer.,  75  [PMID:36031020] [10.1016/j.bmcl.2022.128951]

Source

Source(1):

• Scientific Literature